

Strong CERAMENT® Results Presented at EBJIS

BONESUPPORT™, a leading company in orthobiology for the treatment of bone injuries, announced that strong study results were presented at the European Bone and Joint Infection Society (EBJIS) meeting, September 11–13, 2025. The study which was conducted in South Africa, demonstrates that CERAMENT® G and CERAMENT® V can deliver the same excellent outcomes for trauma patients with infection in a developing market as previously shown in studies from, among others, the Oxford Bone Infection Unit, UK.

The study included 103 patients with post-traumatic infection (80% with open fractures and 20% with closed fractures) or chronic bone infection, treated with CERAMENT G or CERAMENT V in a one-stage procedure. At follow-up after 11 months, treatment success, defined as complete regression of infection without recurrence, as observed in **96.1%** of patients. No patients required amputation. The results confirm that CERAMENT is both effective and safe, even in resource-limited settings.

The study is particularly significant as it focuses on trauma patients who developed infections, a clinically complex and resource-demanding patient group. Achieving these results in a developing market shows that CERAMENT is not dependent on advanced infrastructure but can be used broadly and effectively. A previous study from the Oxford Bone Infection Unit demonstrated 94% infection-free outcomes after six years (96% after one year), results which are now confirmed in a new context.

“The study shows that CERAMENT works even in countries with limited resources. Its simplicity, versatility, and clinical effectiveness give us great confidence in its global potential,” said Torbjörn Sköld, CEO of BONESUPPORT.

For more information contact:

BONESUPPORT AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

Press Release
15 September 2025 09:40:00 CEST



About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 899 million in 2024. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

Strong CERAMENT® Results Presented at EBJIS